1-4 of 4
Stephan G. Klinz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 4830: Preclinical anti-tumor activity of nanoliposomal irinotecan (Nal-IRI, MM-398) + 5-FU + oxaliplatin in pancreatic cancer

Daniel F. Gaddy, Helen Lee, Nancy Paz, Shannon C. Leonard, Ashish Kalra, Ninfa L. Straubinger, Robert M. Straubinger, Bryan M. Gillard, Michael T. Moser, Daryl C. Drummond, Stephan G. Klinz, Bart S. Hendriks, Jonathan B. Fitzgerald
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 4830.
https://doi.org/10.1158/1538-7445.AM2016-4830
Published: 15 July 2016
View article titled, Abstract 4830: Preclinical anti-tumor activity of nanoliposomal irinotecan (Nal-IRI, MM-398) + 5-FU + oxaliplatin in pancreatic cancer
Journal Articles

Abstract P5-01-06: Characterization of metastatic breast cancer lesions with ferumoxytol MRI and treatment response to MM-398, nanoliposomal irinotecan (nal-IRI)

Jasgit C Sachdev, Ramesh K Ramanathan, Natarajan Raghunand, Jaeyeon Kim, Stephan G Klinz, Eliel Bayever, Jonathan B Fitzgerald, Ronald L Korn
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P5-01-06.
https://doi.org/10.1158/1538-7445.SABCS14-P5-01-06
Published: 01 May 2015
View article titled, Abstract P5-01-06: Characterization of metastatic breast cancer lesions with ferumoxytol MRI and treatment response to MM-398, nanoliposomal irinotecan (nal-IRI)
Journal Articles

Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion

Ashish V. Kalra, Jaeyeon Kim, Stephan G. Klinz, Nancy Paz, Jason Cain, Daryl C. Drummond, Ulrik B. Nielsen, Jonathan B. Fitzgerald
Journal: Cancer Research
Series: Author Choice
Cancer Res (2014) 74 (23): 7003–7013.
https://doi.org/10.1158/0008-5472.CAN-14-0572
Published: 30 November 2014
View article titled, Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion
Open the PDF for Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion in another window
Includes: Supplementary data
Journal Articles

Abstract CT224: Pilot study in patients with advanced solid tumors to evaluate feasibility of ferumoxytol (FMX) as tumor imaging agent prior to MM-398, a nanoliposomal irinotecan (nal-IRI)

Ramesh K. Ramanathan, Ronald L. Korn, Jasgit C. Sachdev, Gerald J. Fetterly, Katie Marceau, Vickie Marsh, John M. Neil, Ronald G. Newbold, Natarajan Raghunand, Joshua Prey, Stephan G. Klinz, Eliel Bayever, Jonathan B. Fitzgerald
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): CT224.
https://doi.org/10.1158/1538-7445.AM2014-CT224
Published: 01 October 2014
View article titled, Abstract CT224: Pilot study in patients with advanced solid tumors to evaluate feasibility of ferumoxytol (FMX) as tumor imaging agent prior to MM-398, a nanoliposomal irinotecan (nal-IRI)